Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrially encoded NADH:ubiquinone oxidoreductase subunit 5 (MT-ND5) is a core protein component of complex I in the mitochondrial respiratory chain, located in the inner mitochondrial membrane[1][5]. MT-ND5 is responsible for coupling NADH oxidation to proton translocation across the membrane, facilitating ATP synthesis via oxidative phosphorylation[3][5]. Mutations in the MT-ND5 gene impair electron transport, reduce ATP production, alter mitochondrial membrane potential, and are implicated in a broad spectrum of mitochondrial disorders—including MELAS, Leigh syndrome, and Leber hereditary optic neuropathy. MT-ND5 is considered essential for proper mitochondrial energy metabolism, and genetic variations are important biomarkers for mitochondrial and neurodegenerative diseases[1][3][5].
Inhibition of electron transfer from NADH to ubiquinone, leading to reduction in ATP production and increased production of reactive oxygen species (with complex I inhibitors like rotenone)[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrially encoded NADH:ubiquinone oxidoreductase subunit 5 (MT-ND5).